Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Operations (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Cash from Operations for 6 consecutive years, with 28542000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 70.65% to 28542000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 82235000.0 through Dec 2025, down 87.69% year-over-year, with the annual reading at 82235000.0 for FY2025, 87.69% down from the prior year.
  • Cash from Operations for Q4 2025 was 28542000.0 at Janux Therapeutics, down from 12856000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 5563000.0 in Q1 2021, with the low at 28542000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 11826100.0, with a median of 11811000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations plummeted 543.4% in 2021, then soared 80.95% in 2024.
  • Over 5 years, Cash from Operations stood at 10481000.0 in 2021, then fell by 13.66% to 11913000.0 in 2022, then rose by 16.89% to 9901000.0 in 2023, then crashed by 68.92% to 16725000.0 in 2024, then tumbled by 70.65% to 28542000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 28542000.0, 12856000.0, and 23813000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.